Use of Akkermansia muciniphila in preparing products for preventing, treating and / or assisting in treating cardiovascular diseases

Through the application of the Akkermansia muciniphila strain, the inadequacy of cardiovascular disease, especially myocardial infarction treatment was solved, which significantly inhibited inflammatory factors, improved cardiac function, and achieved protective effect on myocardial injury.

CN116999468BActive Publication Date: 2024-11-15THANKCOME BIOLOGICAL SCI & TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311048099.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-18
Publication Date
2024-11-15
Estimated Expiration
2043-08-18

AI Technical Summary

Technical Problem

The prior art lacks effective treatments to prevent and treat cardiovascular diseases, especially myocardial infarction, and the myocardial reperfusion process may lead to irreversible damage, and new treatments are needed to protect the myocardium.

Method used

Akkermansia muciniphila strain (CGMCC No. 20955) was developed. This strain can significantly inhibit the expression of TNF-α, IL-1β, and IL-18, have good anti-inflammatory effects, and pass through its fermentation broth, fermentation broth supernatant, and live. Bacteria or dead bacteria are used in the prevention, treatment and auxiliary treatment of cardiovascular diseases.

Benefits of technology

It effectively reduces myocardial injury in mice with acute myocardial infarction, improves heart function, significantly inhibits the expression of inflammatory factors, reduces myocardial damage, and improves cardiac function indicators, and has significant anti-inflammatory effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116999468B_ABST
    Figure CN116999468B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of microbial technology, and specifically relates to the use of Akkermansia muciniphila in the preparation of products for the prevention, treatment and / or auxiliary treatment of cardiovascular diseases. The present invention provides Akkermansia muciniphila, which has been deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on October 26, 2020, with a deposit number of CGMCC No. 20955. The bacteria can effectively reduce the occurrence of myocardial infarction, effectively reduce the level of cTnⅠ, CK-MB and LDH activity in serum, and reduce myocardial damage; significantly inhibit the expression of TNF-α, IL-1β, and IL-18, have good anti-inflammatory effects, and provide a new strategy for the prevention and treatment of myocardial infarction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of microbial technology and specifically relates to Akkermansia muciniphila Application in the preparation of products for the prevention, treatment and / or auxiliary treatment of cardiovascular diseases. Background Art

[0002] Cardiovascular disease (CVD), including coronary heart disease, hypertension, acute myocardial infarction and heart failure, is the leading cause of death from non-communicable diseases worldwide. The incidence and mortality of CVD are both among the highest in my country. With the increase of risk factors such as smoking and unhealthy diet, the number of CVD patients is still increasing and the age of onset is tending to be younger. Acute myocardial infarction (AMI) is myocardial necrosis caused by acute and persistent ischemia and hypoxia of the coronary arteries. AMI is a cardiovascular disease that seriously endangers human health. Although the diagnosis and treatment technology has been greatly improved compared with the past, AMI and the resulting heart failure are still diseases with extremely high morbidity and mortality worldwide. For patients with AMI, timely myocardial reperfusion with percutaneous coronary intervention (PPCI) is the most effective treatment. However, the myocardial reperfusion process itself can induce myocardial cell death. This phenomenon is called "myocardial reperfusion injury (IRI)", and its irreversible consequences include microvascular occlusion and further myocardial infarction. Therefore, finding an effective treatment to prevent myocardial ischemia in patients with AMI has become an important research hotspot for cardioprotection.

[0003] In recent years, studies have shown that intestinal flora imbalance and changes in the levels of its metabolites are important factors that promote the occurrence and development of multiple systemic diseases, including CVD. Finding strategies for CVD treatment from the perspective of intestinal flora is a current research hotspot. Probiotics are a class of living microorganisms that can bring multiple benefits to the body, with multiple functions such as anti-inflammation, anti-oxidative stress, regulation of intestinal flora, and protection of the intestinal barrier. With the introduction of concepts such as the heart-gut axis, brain-gut axis, and lung-gut axis, probiotics have been widely used in the research of the cardiovascular system, nervous system, and respiratory system.

[0004] Patent CN113330109A relates to Akkermansia muciniphila SNUG-61027 strain (deposit number KCTC13530BP) and its use. Specifically, a composition for appetite control or prevention, improvement, alleviation or treatment of metabolic diseases, a use for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases, and a method for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases using the composition are provided, wherein the composition comprises the strain, or its culture fluid, or B2UM07 protein isolated therefrom as an active ingredient, and the metabolic disease is impaired glucose tolerance, diabetes, arteriosclerosis, hyperlipidemia, hypercholesterolemia, fatty liver, cardiovascular disease or obesity.

[0005] There is no specific drug for the treatment of myocardial infarction, and currently it is mainly treated with comprehensive measures. Therefore, there is a lack of effective treatments for cardiovascular diseases, and the clinical demand for cardiovascular disease drugs is not met, and there is an urgent need to develop other effective therapeutic drugs.

[0006] The present invention is based on the microbial resources independently developed by the inventor: the deposit number is CGMCC No.20955 Akkermansia muciniphila (Other patents have been submitted on the same day), and downstream application technology development is being carried out.

[0007] The inventor obtains Akkermansia muciniphila Afterwards, application experiments were conducted in many fields including cardiovascular disease, analgesia, anti-tumor, cognitive disease, metabolic disease, inflammatory disease, bone and joint disease, and positive experimental results were obtained in some fields.

[0008] Taking into account the relevant provisions of the Patent Law on unity, protection is requested separately for each indication that does not have unity.

[0009] The present invention is directed to the protection of application technology for treating, assisting in the treatment or preventing cardiovascular diseases.

[0010] Since the relevant evidences such as microbial identification and performance test were published in the microbial patent filed on the same day, in order to facilitate the examination of the present invention and quickly understand the inventor’s previous work, the relevant evidences of the microbial identification and performance test were published in the microbial patent filed on the same day. Akkermansia muciniphila A brief disclosure of relevant information.

[0011] Akkermansia muciniphila :

[0012] The conclusive information in this section is for the convenience of the review of the present invention, but is not intended to limit the scope of protection of the present invention. The specific experimental process and experimental results are recorded in the microbiological patent filed on the same day as the present invention.

[0013] 1. Akkermansia muciniphila Obtained by separation and screening by the inventors.

[0014] 2. Akkermansia muciniphila Deposit information: The deposit number is: CGMCC No. 20955.

[0015] 3. Akkermansia muciniphila 16srRNA: SEQ ID NO.1.

[0016] 4. Akkermansia muciniphila Physiological and biochemical properties:

[0017] (1) Hydrophobicity: It increases with time and reaches more than 30% at 60 min.

[0018] (2) Self-aggregation: It increases with time and tends to be stable at 20 h, remaining at around 52%.

[0019] (3) Gastrointestinal fluid tolerance:

[0020] The survival rate in gastric juice showed a decreasing trend with the extension of time, and the survival rate was about 85% at 240 min;

[0021] The survival rate in intestinal fluid showed an overall downward trend, and was above 80% at 240 min.

[0022] (4) Biofilm formation ability: weak.

[0023] (5) Acute toxicity test:

[0024] The results of bacterial reverse mutation test showed that the strain had no mutagenicity;

[0025] Mice were acutely gavaged with high, medium, and low doses of Akkermansia muciniphila , no mortality occurred;

[0026] There was no significant difference in the daily body weight changes between the test group mice and the control saline group;

[0027] During the acute gavage period, there was no significant difference in the daily food intake of the test mice and the control saline group mice;

[0028] During the acute gavage period, there was no significant difference in the daily changes in blood glucose between the test mice and the control saline group mice;

[0029] There were no significant differences in the blood parameters between the acute gavage group and the control saline group;

[0030] In the liver, the triglyceride levels in the test mice were significantly lower than those in the control saline group mice;

[0031] There was no significant difference in serum triglyceride levels between the test mice and the control mice;

[0032] There was no significant difference in cholesterol levels in serum and liver between the test mice and the control mice;

[0033] There was no significant difference in the bile acid levels in serum and liver between the test mice and the control mice;

[0034] There was no significant difference in glucose levels in serum and liver between the test mice and the control mice;

[0035] There was no significant difference in the total protein levels in serum and liver between the test mice and the control mice;

[0036] There was no significant difference in the activity of alanine aminotransferase in serum and liver between the test mice and the control mice.

[0037] There was no significant difference in the activity of aspartate aminotransferase in serum and liver between the test mice and the control mice;

[0038] There was no significant difference in serum creatinine content between the test mice and the control mice;

[0039] There was no significant difference in the urea nitrogen concentration in the serum between the test mice and the control mice;

[0040] There was basically no significant difference in the weight of the heart, liver, spleen, kidney, thymus, brain, testis, lung, stomach and intestine of the test mice and the control mice;

[0041] There was no significant pathological damage in the liver and kidneys of the test mice and the control group mice.

[0042] (6) Subchronic toxicity test:

[0043] Mice were gavaged with high, medium, and low doses of Akkermansia muciniphila , no mortality occurred;

[0044] There was no significant difference in the weekly body weight change between the test group mice and the control saline group;

[0045] During the continuous gavage period, there was no significant difference in the weekly changes in food intake between the test mice and the control saline group mice;

[0046] During the continuous gavage period, the changes in blood glucose in the mice given a medium dose of oral administration were significantly different from those in the control saline group, but there were no significant differences between the other groups and the control group.

[0047] There were no significant differences in the blood parameters between the mice in the gavage group and the control saline group;

[0048] There was no significant difference in triglyceride levels in the liver and serum between the test mice and the control mice;

[0049] There was no significant difference in cholesterol levels in the liver and serum between the test mice and the control mice;

[0050] The bile acid levels in the liver of the mice given the medium dose and the control group were significantly different, while there were no significant differences in the serum and liver between the other groups and the control group.

[0051] There was no significant difference in glucose levels in the liver and serum between the test mice and the control mice;

[0052] There was no significant difference in the total protein content in the liver and serum between the test mice and the control mice;

[0053] There was no significant difference in the activity of alanine aminotransferase in serum and liver between the test mice and the control mice.

[0054] There was no significant difference in the activity of aspartate aminotransferase in serum and liver between the test mice and the control mice;

[0055] There was no significant difference in serum creatinine content between the test mice and the control mice;

[0056] There was no significant difference in the urea nitrogen concentration in the serum between the test mice and the control mice;

[0057] There was basically no significant difference in the weight of the heart, liver, spleen, kidney, thymus, brain, testis, lung, pancreas, stomach and intestine between the test mice and the control mice;

[0058] There was no significant pathological damage in the liver and kidneys of the test mice and the control mice;

[0059] There was no significant difference in blood sugar regulation ability between the test mice and the control group mice.

[0060] (7) Akkermansia muciniphila Drug sensitivity analysis:

[0061] Determined Akkermansia muciniphila The strains were sensitive to ampicillin, ceftriaxone, ceftriaxone, meropenem, tetracycline, moxifloxacin, and chloramphenicol. Summary of the invention

[0062] In order to solve the above problems, the present invention provides Akkermansia muciniphila , was deposited in the General Microbiology Center of China Microbiological Culture Collection Administration on October 26, 2020, with the deposit number: CGMCC No. 20955. The bacterium can effectively reduce the occurrence of myocardial infarction, significantly inhibit the expression of TNF-α, IL-1β, and IL-18, and has a good anti-inflammatory effect.

[0063] The present invention is directed to Akkermansia muciniphila Request for protection of downstream application technology.

[0064] Specifically Akkermansia muciniphila Application in cardiovascular diseases.

[0065] Specifically, in terms of application fields, the aforementioned applications include:

[0066] 1. Therapeutic methods and pharmaceutical uses Akkermansia muciniphila Applied to the prevention, treatment, auxiliary prevention and auxiliary treatment of cardiovascular diseases;

[0067] 2. For the purpose of raw material preparation Akkermansia muciniphila Used in the prevention, treatment, auxiliary prevention and auxiliary treatment of cardiovascular diseases.

[0068] The present invention uses model mice as an example to verify Akkermansia muciniphila The application in cardiovascular diseases should not be limited to therapeutic methods or pharmaceutical uses based on the commonness of animal experiments in the medical field.

[0069] Specifically, in terms of the types of cardiovascular diseases, the aforementioned applications include but are not limited to: coronary heart disease, heart failure, hypertension, arrhythmia and / or cardiomyopathy.

[0070] Based on the principle that the occurrence of various cardiovascular diseases is due to the production or release of certain substances in the body caused by the disease, which in turn affects the balance of the cardiovascular system. Akkermansia muciniphila Experiments on a specific cardiovascular disease (coronary heart disease) can reasonably be generalized or inferred to be equally applicable or at least have application potential in other cardiovascular diseases.

[0071] More specifically, the coronary heart disease is angina pectoris and / or myocardial infarction.

[0072] More specifically, the myocardial infarction is acute myocardial infarction, non-ST-segment elevation myocardial infarction, right ventricular myocardial infarction, atrial myocardial infarction and / or post-myocardial infarction pericarditis.

[0073] Preferably, the myocardial infarction is acute myocardial infarction.

[0074] More specifically, the heart failure can be left heart failure, right heart failure or total heart failure.

[0075] More specifically, the hypertension may be primary hypertension or secondary hypertension.

[0076] More specifically, the cardiac arrhythmia may be sinus arrhythmia, atrial arrhythmia, ventricular arrhythmia and / or heart block.

[0077] More specifically, the cardiomyopathy may be dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy and / or myocarditis.

[0078] Specifically, in terms of raw material form, the aforementioned application includes the use of Akkermansia muciniphila fermentation broth, fermentation broth supernatant, fermentation broth precipitate, live bacteria, dead bacteria and / or any direct or indirect Akkermansia muciniphila The ingredients, components, constituents, metabolites of the drug; and the presence or absence of current and future excipients permitted in a specific application area.

[0079] More specifically, the fermentation liquid refers to the liquid obtained by inoculating bacteria into a culture medium and culturing for a period of time.

[0080] More specifically, the fermentation broth supernatant refers to the clarified liquid on the upper layer of the fermentation broth after centrifugation; it contains abundant metabolites of bacterial growth and reproduction and some bacterial fragments. The acidic substances and bacteriocins secreted by bacteria have antagonistic and killing effects on harmful bacteria; the amino acids and synthesized vitamins after bacteria decompose food are all in the culture medium, and also include enzymes secreted by bacteria that are useful to the human body; and some bacterial components also have an immune-promoting effect on the human body.

[0081] More specifically, the fermentation liquid precipitate refers to the liquid precipitate obtained by centrifugation, including free protein, residual bacteria, broken cells, and residues of the culture matrix, mainly protein and intracellular matrix.

[0082] More specifically, the live bacteria, also called active flora, can colonize and multiply in the intestine, which is beneficial to increase the number of beneficial bacteria.

[0083] More specifically, the dead bacteria are microorganisms that have lost their vitality and are unable to grow and reproduce. The probiotics lose their vitality due to the production process, such as high temperature treatment or excessive drying.

[0084] Specifically, in the field of medicine, the medicine includes:

[0085] (1) Akkermansia muciniphila fermentation broth, fermentation broth supernatant, fermentation broth precipitate, live bacteria and / or dead bacteria;

[0086] (2) Pharmaceutically acceptable excipients.

[0087] More specifically, the pharmaceutically acceptable excipient is selected from one or a combination of two or more of a buffer, an excipient, a diluent, a preservative, a wetting agent, an emulsifier, a lubricant, a flavor, a thickener, a stabilizer, a solubilizer, a sweetener, an antibacterial agent, a suspending agent, a suspending aid, and an antioxidant.

[0088] Preferably, the pharmaceutically acceptable excipient is selected from at least one of alginate, water, syrup, methylcellulose, gelatin, calcium silicate, starch, gum arabic, mineral oil, cellulose, calcium phosphate, propyl hydroxybenzoate, fine crystalline cellulose, methyl hydroxybenzoate, magnesium stearate lactose, mannose, polyvinyl pyrrolidone and talc.

[0089] More specifically, the dosage form of the drug is tablets, liquids, capsules, powders, suppositories and granules.

[0090] More specifically, the medicine comprises other medicines for treating cardiovascular diseases.

[0091] More specifically, the auxiliary material is selected from fillers, capsule shell materials, solvents, stabilizers, flavoring agents, sweeteners, pigments, or a combination of two or more thereof.

[0092] Preferably, the filler is selected from at least one of starch, corn flour and grapes;

[0093] The capsule shell material is selected from at least one of gelatin, hydroxypropyl methylcellulose and polyvinyl alcohol;

[0094] The solvent is selected from at least one of water, alcohol, glycerol and ethanol;

[0095] The stabilizer is selected from at least one of an antioxidant and a preservative;

[0096] The flavoring agent is selected from at least one of natural flavors and artificial flavors;

[0097] The sweetener is selected from at least one of natural sweeteners and artificial sweeteners;

[0098] The pigment is selected from at least one of natural pigment and artificial pigment.

[0099] Specifically, in terms of active dose, the above fields Akkermansia muciniphila The number of viable bacteria is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

[0100] Preferably, the Akkermansia muciniphila The number of viable bacteria is 1×10 8 -1×10 12 CFU / g or 1×10 8 -1×10 12 CFU / mL.

[0101] More preferably, the Akkermansia muciniphila The number of viable bacteria is 1×10 9 -1×10 12 CFU / g or 1×10 9 -1×10 12 CFU / mL, such as 1×10 9 CFU / g (CFU / mL), 2×10 9 CFU / g (CFU / mL), 3×10 9 CFU / g (CFU / mL), 4×10 9 CFU / g (CFU / mL), 5×10 9 CFU / g (CFU / mL), 6×10 9CFU / g (CFU / mL), 7×10 9 CFU / g (CFU / mL), 8×10 9 CFU / g (CFU / mL), 9×10 9 CFU / g (CFU / mL), 10×10 9 CFU / g, etc. Other point values ​​within this numerical range can be selected.

[0102] The present invention also provides a method for treating cardiovascular disease, which comprises administering Akkermansia muciniphila .

[0103] Specifically, the cardiovascular disease patients are patients clinically diagnosed with coronary heart disease, heart failure, hypertension, arrhythmia and / or cardiomyopathy.

[0104] Specifically, the method of administration is selected from oral administration, intravenous injection, topical administration, intradermal administration and / or subcutaneous administration.

[0105] Specifically, a medicament comprising the following (1) and (2) is administered to a patient with cardiovascular disease:

[0106] (1) Akkermansia muciniphila fermentation broth, fermentation broth supernatant, fermentation broth precipitate, live bacteria and / or dead bacteria;

[0107] (2) Pharmaceutically acceptable excipients.

[0108] More specifically, the pharmaceutically acceptable excipient is selected from one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, excipients, diluents, lubricants, antibacterial agents, suspending agents, suspending aids, solubilizers, thickeners, stabilizers, sweeteners and flavors.

[0109] Preferably, the pharmaceutically acceptable excipient is at least one selected from lactose, mannose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

[0110] More specifically, the medicine comprises other medicines for treating cardiovascular diseases.

[0111] The present invention also provides a method for generating, deriving, or developing a method based on the above application. Akkermansia muciniphila Treatment approaches for cardiovascular disease.

[0112] Specifically, based on Akkermansia muciniphilaThe purpose of treating or preventing cardiovascular diseases is to improve the strains and produce, derive, or derive strains with better effects in treating or preventing cardiovascular diseases. Akkermansia muciniphila The improvement methods are traditional methods and genetic engineering methods.

[0113] More specifically, the conventional method may be a physical method, a chemical method and / or a selection method.

[0114] More specifically, the physical method refers to the use of radiation or high pressure to induce mutations, thereby achieving strain improvement.

[0115] Preferably, the radiation method comprises ultraviolet radiation and / or X-ray radiation;

[0116] The high pressure method may be to expose the microorganisms to a high pressure environment to cause them to undergo adaptive changes.

[0117] More specifically, the chemical method refers to the use of chemical agents to induce mutation of bacterial strains.

[0118] Preferably, the chemical agent may be nitrite, acetylcholine and / or nitrogen mustard.

[0119] More specifically, the selection method refers to the process of selecting microorganisms with excellent traits for reproduction, thereby achieving strain improvement.

[0120] Preferably, the selection method is used to improve the metabolic pathways and / or growth conditions of microorganisms to obtain better effects in treating or preventing cardiovascular diseases. Akkermansia muciniphila .

[0121] More specifically, the genetic engineering method may be gene cloning, gene knockout, gene editing and / or synthetic biology, so as to obtain strains with better effects in treating or preventing cardiovascular diseases.

[0122] More specifically, the gene cloning refers to cutting out the target gene from one cell and inserting it into another cell to achieve the expression of the target gene in the new host, so as to enhance the effect of the original strain in treating or preventing cardiovascular diseases.

[0123] More specifically, the gene knockout refers to deleting the target gene through technical means to achieve the regulation of microbial traits to obtain strains with better effects in treating or preventing cardiovascular diseases.

[0124] More specifically, the gene editing refers to the precise modification of the target gene sequence through technical means to achieve the regulation of microbial traits in order to obtain strains with better effects in treating or preventing cardiovascular diseases.

[0125] More specifically, the synthetic biology refers to the use of chemical synthesis machine technology to construct new gene sequences and introduce them into microorganisms to achieve regulation of microbial traits in order to obtain strains that are better at treating or preventing cardiovascular diseases.

[0126] The present invention also provides a method for generating, deriving, or developing a method based on the above application. Akkermansia muciniphila products.

[0127] Specifically, a drug for treating or preventing cardiovascular disease, the drug comprising:

[0128] (1) generated, derived, derived Akkermansia muciniphila fermentation broth, fermentation broth supernatant, fermentation broth precipitate, live bacteria and / or dead bacteria;

[0129] (2) Pharmaceutically acceptable excipients.

[0130] More specifically, the pharmaceutically acceptable excipient is selected from one or a combination of two or more of a buffer, an excipient, a diluent, a preservative, a wetting agent, an emulsifier, a lubricant, a flavor, a thickener, a stabilizer, a solubilizer, a sweetener, an antibacterial agent, a suspending agent, a suspending aid, and an antioxidant.

[0131] Preferably, the pharmaceutically acceptable excipient is selected from at least one of alginate, water, syrup, methylcellulose, gelatin, calcium silicate, starch, gum arabic, mineral oil, cellulose, calcium phosphate, propyl hydroxybenzoate, fine crystalline cellulose, methyl hydroxybenzoate, magnesium stearate lactose, mannose, polyvinyl pyrrolidone and talc.

[0132] More specifically, the dosage form of the drug is tablets, liquids, capsules, powders, suppositories and granules.

[0133] More specifically, the medicine comprises other medicines for treating cardiovascular diseases.

[0134] More specifically, the auxiliary material is selected from fillers, capsule shell materials, solvents, stabilizers, flavoring agents, sweeteners, pigments, or a combination of two or more thereof.

[0135] Preferably, the filler is selected from at least one of starch, corn flour and grapes;

[0136] The capsule shell material is selected from at least one of gelatin, hydroxypropyl methylcellulose and polyvinyl alcohol;

[0137] The solvent is selected from at least one of water, alcohol, glycerol and ethanol;

[0138] The stabilizer is selected from at least one of an antioxidant and a preservative;

[0139] The flavoring agent is selected from at least one of natural flavors and artificial flavors;

[0140] The sweetener is selected from at least one of natural sweeteners and artificial sweeteners;

[0141] The pigment is selected from at least one of natural pigment and artificial pigment.

[0142] Specifically, in terms of active dose, the above fields are generated, derived, and derived from Akkermansia muciniphila The number of viable bacteria is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

[0143] Preferably, the Akkermansia muciniphila The number of viable bacteria is 1×10 8 -1×10 12 CFU / g or 1×10 8 -1×10 12 CFU / mL.

[0144] More preferably, the Akkermansia muciniphila The number of viable bacteria is 1×10 9 -1×10 12 CFU / g or 1×10 9 -1×10 12 CFU / mL, such as 1×10 9 CFU / g (CFU / mL), 2×10 9 CFU / g (CFU / mL), 3×10 9 CFU / g (CFU / mL), 4×10 9 CFU / g (CFU / mL), 5×10 9 CFU / g (CFU / mL), 6×10 9 CFU / g (CFU / mL), 7×10 9 CFU / g (CFU / mL), 8×10 9 CFU / g (CFU / mL), 9×10 9 CFU / g (CFU / mL), 10×10 9 CFU / g, etc. Other point values ​​within this numerical range can be selected.

[0145] The technical effects achieved by the present invention are:

[0146] (1) It effectively reduced the left ventricular end-diastolic diameter and left ventricular end-systolic diameter of mice in the acute myocardial infarction group, increased the shortening fraction (FS) and ejection fraction (EF), and effectively improved the function of the infarcted heart.

[0147] (2) It can effectively reduce serum cTnⅠ levels, CK-MB and LDH activities, and significantly reduce myocardial damage.

[0148] (3) It significantly inhibits the expression of TNF-α, IL-1β, and IL-18, and has a good anti-inflammatory effect.

[0149] Storage Instructions:

[0150] Strain name: AKK PROBIO;

[0151] Deposit number: CGMCC No. 20955;

[0152] Category naming: Akkermansia muciniphila ;

[0153] Deposit date: October 26, 2020;

[0154] Depository: General Microbiology Center, China Microbiological Culture Collection Administration;

[0155] Address of the preservation unit: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0156] Figure 1 Figure 2 shows the levels of cardiac troponin Ⅰ (cTn Ⅰ) in serum of four groups of experimental mice.

[0157] Figure 2 The expression levels of interleukin-1β (IL-1β) in myocardial tissue of four groups of experimental mice.

[0158] Figure 3 The expression levels of interleukin-18 (IL-18) in myocardial tissue of four groups of experimental mice. DETAILED DESCRIPTION

[0159] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0160] Nouns and terms:

[0161] Cardiac Troponin Ⅰ (cTnⅠ): It is a regulatory protein for myocardial muscle contraction and is mainly used to screen for diseases related to myocardial damage or necrosis, such as myocardial infarction, viral myocarditis, acute heart failure, renal failure and myocardial hypoxia.

[0162] Creatine Kinase MB (CK-MB): Mainly exists in the myocardium. Elevated CK-MB index may indicate myocardial damage, such as myocardial infarction, pericarditis, myocardial damage and other diseases.

[0163] Lactate dehydrogenase (LDH): A type of glycolytic enzyme, it is generally included in myocardial enzyme spectrum examination and liver function test. It is a commonly used examination indicator in clinical practice. It is generally used to determine the degree of myocardial damage and liver cell damage. It can assist in the diagnosis and differentiation of myocardial infarction, acute hepatitis, and active liver disease.

[0164] Tumor necrosis factor-α (TNF-α): is a pro-inflammatory cytokine produced primarily by macrophages and monocytes and is involved in normal inflammatory and immune responses. TNF-α production is increased in many pathological conditions, including sepsis, malignancies, heart failure, and chronic inflammatory diseases.

[0165] Interleukin-1β (IL-1β): It is produced by activated macrophages in the form of proprotein and processed into active form by caspase-1 (CASP1 / ICE) proteolysis. IL-1β is an important mediator of inflammatory response and participates in a variety of cellular activities, including cell proliferation, differentiation and apoptosis.

[0166] Interleukin-18 (IL-18): is a protein that in humans is encoded by the IL18 gene. The protein encoded by this gene is a pro-inflammatory cytokine. Many cell types, including hematopoietic and non-hematopoietic cells, have the potential to produce IL-18.

[0167] The present invention Akkermansia muciniphila That is AKK PROBIO.

[0168] Example 1 Cultivation of AKK PROBIO

[0169] (1) Culture medium

[0170] Solid plate culture: BHI (Brain Heart Infusion, OXOID, Catalog No.: CM1032B) + 5% sheep blood

[0171] Weigh a certain volume of BHI powder according to the finished product requirements, add agar powder at a ratio of 20g / L, dilute to the corresponding volume, and sterilize at 121℃ for 20min. After sterilization, add 5% sterile defibrinated sheep blood when it cools to 53℃ (not hot to hold), shake well and pour 15-20mL into a plate for later use.

[0172] (2) Culture conditions

[0173] Culture temperature: 37°C;

[0174] Culture conditions: completely anaerobic;

[0175] Liquid fermentation broth culture: BHI;

[0176] Culture temperature: 37°C;

[0177] Culture conditions: Completely anaerobic culture on 8 layers of gauze.

[0178] (3) Expansion culture of bacterial strains

[0179] Level 1: Take a 2 ml glycerol tube and inoculate it into a 9 ml BHI test tube with 10% inoculum, and culture anaerobically at 37°C for 24-48 hours.

[0180] Secondary: Take the primary fermentation test tube and inoculate it into a conical flask containing 90 mL of BHI at a 5% inoculation rate, and culture anaerobically at 37°C for 24 h.

[0181] Level 3: Take the fermentation liquid from the second-level Erlenmeyer flask and inoculate it into a Erlenmeyer flask containing 300 mL of BHI at a 5% inoculation rate. Incubate anaerobically at 37°C for 13 h and store in a 20% glycerol tube at -80°C.

[0182] Example 2 Animal Experiment

[0183] 2.1 Animals

[0184] A total of 40 8-week-old female C57BL / 6 mice (Shanghai Model Organisms Technology Co., Ltd.) weighing 18-22 g were used. They were free of specific pathogens and were fed for one week before the experiment. They were allowed to eat and drink freely in a breeding environment that met SPF requirements.

[0185] 2.2 Reagents and instruments

[0186] Positive drug, metoprolol succinate sustained-release tablets, the main ingredient is equivalent to metoprolol tartrate 50 mg, each tablet contains 47.5 mg of metoprolol succinate, manufacturer: AstraZeneca AB, product batch number: SYPB.

[0187] Mouse cardiac troponin I (cTnⅠ) ELISA detection kit, Shanghai Xuanya Biotechnology Co., Ltd., catalog number: XY-SJH-XS1395.

[0188] Mouse creatine kinase isoenzyme MB (CK-MB) ELISA detection kit, Shenzhen Ruiqing Bioinformatics Technology Co., Ltd., catalog number: RQ-P-M0114.

[0189] Mouse lactate dehydrogenase (LDH) ELISA detection kit, Shanghai Chutai Biotechnology Co., Ltd., catalog number: CT68539.

[0190] Mouse TNF-α ELISA detection kit, Shanghai Xuanya Biotechnology Co., Ltd., catalog number: XY-SJH-XS1204.

[0191] Interleukin 1β (IL-1β) ELISA detection kit, Shanghai Xinyu Biotechnology Co., Ltd., catalog number: XYA563Mu.

[0192] Mouse IL-18 ELISA detection kit, Shanghai Xuanya Biotechnology Co., Ltd., catalog number: XY-SJH-XS1007.

[0193] 2.3 Acute myocardial infarction modeling and drug intervention

[0194] Modeling method: The myocardial infarction model was established by ligating the left anterior descending branch of the coronary artery.

[0195] Eight-week-old mice were randomly divided into four groups: sham operation group, acute myocardial infarction group, positive drug group, and AKK PROBIO group, with 10 mice in each group. After fasting for 12 hours before surgery, the mice were anesthetized, shaved, and disinfected. The skin was cut open, the muscles were peeled off with a blunt instrument, and the pericardium was cut open to expose the heart. The left anterior descending branch of the coronary artery was ligated, and pale ligation was observed, indicating successful ligation. In the sham operation group, the suture was only passed through the lower edge of the left atrial appendage without ligation.

[0196] Drug intervention was carried out twice every other day (once in the morning and once in the evening) for 15 days. After the positive drug group was successfully modeled, metoprolol succinate sustained-release tablets were given at the same time every other day, with an intragastric dose of 4 mg / kg; in the AKK PROBIO group, the intragastric dose was 1×10 9 CFU / mouse; the sham operation group and the acute myocardial infarction group were gavaged with an equal amount of normal saline. After the drug intervention, serum and myocardial tissue of mice were collected.

[0197] 2.4 Index detection

[0198] 2.4.1 Echocardiography to detect cardiac function in mice

[0199] The mice in each group were examined by echocardiography using a GE Voluson E8 four-dimensional color Doppler ultrasound instrument, and the cardiac function-related indices were calculated, including left ventricular end-diastolic diameter (LVIDd), left ventricular end-systolic diameter (LVIDs), shortening fraction (FS), and ejection fraction (EF).

[0200] 2.4.2 Detection of cTnⅠ level, CK-MB and LDH activity

[0201] After the whole blood of each group of mice was placed at room temperature for 1 hour, it was centrifuged at 1000×g for 20 minutes to obtain serum samples. Serum cTnⅠ level, CK-MB and LDH activity were detected according to the instructions of ELISA kit.

[0202] 2.4.3 Detection of myocardial tissue inflammation indicators

[0203] The myocardial tissue of mice was obtained, homogenized in an ice bath, centrifuged at 1000×g for 15 min, and the supernatant was used for detection. The expression levels of TNF-α, IL-1β, and IL-18 in myocardial tissue of mice were detected according to the instructions of the ELISA kit.

[0204] 2.5 Test results

[0205] 2.5.1 Cardiac function test results

[0206] The results of cardiac function test are shown in Table 1. Compared with the sham operation group, the left ventricular end-diastolic diameter and left ventricular end-systolic diameter of the mice in the acute myocardial infarction group were significantly increased, and the shortening fraction (FS) and ejection fraction (EF) were significantly decreased. Compared with the acute myocardial infarction group, the above indicators in the positive drug group and the AKK PROBIO group recovered to varying degrees, among which the positive drug group was slightly better than the AKK PROBIO group.

[0207] Table 1

[0208]

[0209] 2.5.2 Results of cTnⅠ levels, CK-MB and LDH activity tests

[0210] The results of cTnⅠ level, CK-MB and LDH activity detection are shown in Table 2. Compared with the sham operation group, the serum cTnⅠ level, CK-MB and LDH activity of mice in the acute myocardial infarction group were significantly increased. Compared with the acute myocardial infarction group, the above indicators in the positive drug group and AKKPROBIO group were downregulated to varying degrees, among which the AKK PROBIO group had a better degree of downregulation of cTnⅠ level than the positive drug group. This shows that both the AKK PROBIO group and the positive drug group can effectively reduce myocardial damage.

[0211] Table 2

[0212]

[0213] 2.5.3 Myocardial tissue inflammation detection results

[0214] The results of myocardial tissue inflammation detection are shown in Table 3. Compared with the sham operation group, the expression levels of TNF-α, IL-1β, and IL-18 in the acute myocardial infarction group were significantly increased. Compared with the acute myocardial infarction group, the expression levels of the above indicators in the positive drug group and the AKK PROBIO group were significantly decreased, among which the two groups had a similar decrease in TNF-α expression level; the AKK PROBIO group had the most obvious decrease in IL-1β and IL-18 expression levels, which were even close to the levels of the sham operation group.

[0215] Table 3

[0216]

[0217] Comparative Example

[0218] Referring to the culture method of Example 1 and the experimental method for detecting myocardial tissue inflammation indicators in Example 2, the AKK PROBIO of the present invention was replaced with the ATCC standard strain of Akkermansia (ATCC BAA 835) to conduct experiments. The specific results are shown in Table 4.

[0219] Table 4

[0220]

[0221] The above results show that the ATCC standard strain of Akkermansia has a lower regulation of the four indicators in Table 4 compared with the acute myocardial infarction group, but the effect is not as good as the positive drug group, and even worse than the AKK PROBIO of the present invention. Therefore, the AKK PROBIO of the present invention can significantly inhibit the expression of TNF-α, IL-1β, IL-18, and cTnⅠ, has a better anti-inflammatory effect, and can significantly reduce myocardial damage.

[0222] Application Example 1: AKK PROBIO live bacteria preparation method

[0223] AKK PROBIO live bacteria culture method

[0224] (1) Culture medium

[0225] Solid plate culture: BHI + 5% sheep blood

[0226] Weigh a certain volume of BHI powder according to the finished product requirements, add agar powder at a ratio of 20g / L, dilute to the corresponding volume, and sterilize at 121℃ for 20min. After sterilization, add 5% sterile defibrinated sheep blood when it cools to 53℃ (not hot to hold), shake well and pour 15-20mL into a plate for later use.

[0227] (2) Culture conditions

[0228] Culture temperature: 37°C;

[0229] Culture conditions: completely anaerobic;

[0230] Liquid fermentation broth culture: BHI;

[0231] Culture temperature: 37°C;

[0232] Culture conditions: Completely anaerobic culture on 8 layers of gauze.

[0233] (3) Expansion culture of bacterial strains

[0234] Level 1: Take a 2 ml glycerol tube and inoculate it into a test tube containing 9 mL BHI at a 10% inoculum volume, and culture anaerobically at 37°C for 24-48 hours.

[0235] Secondary: Take the primary fermentation test tube and inoculate it into a conical flask containing 90 mL of BHI at a 5% inoculation rate, and culture anaerobically at 37°C for 24 h.

[0236] Level 3: Take the fermentation liquid from the second-level Erlenmeyer flask and inoculate it into a Erlenmeyer flask containing 300 mL of BHI at a 5% inoculation rate. Incubate anaerobically at 37°C for 13 h and store in a 20% glycerol tube at -80°C.

[0237] (4) Fermentation tank culture

[0238] The activated bacteria were placed in a large fermentation tank and cultured under the same conditions as above. After the culture was completed, the wet bacteria were obtained by centrifugation.

[0239] Application Example 2: AKK PROBIO dead bacteria preparation method

[0240] The wet bacteria prepared in Example 1 are killed by chemical or physical methods to obtain dead bacteria;

[0241] The chemical method may be gas sterilization and / or liquid sterilization;

[0242] Specifically, the gas sterilization may be ozone, ethylene oxide, formaldehyde, propylene glycol, glycerin or peracetic acid vapor;

[0243] The liquid sterilization agent is a chemical reagent, such as ethanol;

[0244] The physical method may be heat sterilization, light sterilization and / or microwave sterilization;

[0245] Specifically, the thermal sterilization method may be a burning method, a dry baking method, a boiling method and / or a pressure steam sterilization method;

[0246] The light sterilization can be sunlight exposure, ultraviolet irradiation and / or ionizing radiation.

[0247] Application Example 3: An oral medicine containing AKK PROBIO

[0248] The wet bacteria prepared in Example 1 are mixed with auxiliary materials in a certain ratio, and the mixture is made into live bacteria tablets, capsules, granules, etc. by freeze drying, spray drying, tableting, etc.;

[0249] Alternatively, the wet bacteria prepared in Example 1 are subjected to cell disruption, and then the beneficial components are extracted by appropriate techniques; the extraction methods include centrifugation, distillation, leaching, extraction, etc., and the specific selection depends on the components contained in the probiotics; the extracted components can be prepared into different dosage forms such as capsules, oral liquids, granules, injections, etc. according to clinical use needs.

[0250] Application Example 4: A yogurt containing AKK PROBIO.

[0251] Raw materials: wet bacteria prepared in Example 1, milk, yogurt, soy milk or milk powder (fresh), yogurt starter (Lactobacillus bulgaricus and Streptococcus thermophilus);

[0252] Take milk preparation as an example:

[0253] Mix fresh milk, yogurt starter and wet bacteria in a certain proportion, stir evenly, cover with plastic wrap and ferment in a warm place (preferably 30-40℃) for 6-8 hours (or overnight), and refrigerate after fermentation.

Claims

1. Akkermansia muciniphila Application in the preparation of a product for treating and / or assisting in the treatment of acute myocardial infarction, characterized in that: The Akkermansia muciniphila The deposit number is: CGMCC No. 20955; Akkermansia muciniphila For live bacteria.

2. The use according to claim 1, characterized in that: The product is a drug or a pharmaceutical raw material.

3. A drug for treating acute myocardial infarction, characterized in that: The medicine comprises: (1) Akkermansia muciniphila of live bacteria; (2) Pharmaceutically acceptable excipients; The Akkermansia muciniphila The deposit number is: CGMCC No. 20955.

4. The drug according to claim 3, characterized in that The dosage form of the medicine is tablet, liquid, capsule, powder, suppository and granule.

5. The drug according to claim 3, characterized in that The drugs described Akkermansia muciniphila The number of viable bacteria is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

6. The drug according to claim 3, characterized in that The medicine includes other medicines for treating acute myocardial infarction.

7. The drug according to any one of claims 3 to 6, characterized in that The pharmaceutically acceptable excipients are selected from one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, excipients, diluents, lubricants, antibacterial agents, suspending agents, suspending aids, solubilizers, thickeners, stabilizers, sweeteners and flavors.